OncoPharm Tazemetostat Withdrawl and RECITE
Mar 19, 2026
They discuss a drug pulled from the market after links to secondary cancers. They review a trial testing romiplostim to raise platelets for patients on oxaliplatin and whether higher chemo dose intensity matters. Safety signals like clotting, marrow issues, and long term risks get attention. They also highlight public-funded trials comparing common treatments.
AI Snips
Chapters
Transcript
Episode notes
Accelerated Approval Can Hide Long Term Harm
- Accelerated approvals can mislead when long-term harms emerge.
- John Bazar highlights tazemetostat's market withdrawal after secondary malignancies outweighed high short-term response rates in follicular lymphoma.
Romiplostim Restores Platelets And Cuts Dose Modifications
- Romiplostim raises platelets and reduces chemo dose modifications for oxaliplatin regimens.
- In RECITE, 84% on romiplostim avoided dose changes versus 36% with placebo, showing clear effect on platelet-driven continuity.
Decide Use Based On Curative Versus Palliative Intent
- Consider clinical intent before using romiplostim; prioritize palliative dose reductions.
- John Bazar advises delaying/reducing oxaliplatin in noncurative settings rather than automatically restoring dose intensity with romiplostim.